Business
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from FDA expected in Q4 2025 Rutherford, NJ, May 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies
About this update from Glucotrack, Inc.
[{"type":"image","alt":"GlucoTrack, Inc.","displaySize":"","headline":null,"caption":"GlucoTrack, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jLjmYeICxeIiiA5nYSpJ3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a","width":300,"height":64}},"lazy":false},{"type":"text","content":"On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025","length":174,"tagName":"p"},{"type":"text","content":"Investigational Device Exemption (IDE) approval for novel CBGM technology from FDA expected in Q4 2025","length":102,"tagName":"p"},{"type":"text","content":"Rutherford, NJ, May 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2025.","length":357,"tagName":"p"},{"type":"text","content":"“I am pleased with the progress we made during the quarter and look forward to commencing our clinical study in Australia, where we expect to continue growing our body of clinical evidence to support the use of our well-differentiated, fully implantable, real-time, multi-year continuous blood glucose monitoring system,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “At the same time, we remain focused on strengthening our capital structure and ensuring that we have the runway to bring our potentially life-improving technology to the millions of diabetes patients who need it most.”","length":619,"tagName":"p"},{"type":"text","content":"First Quarter 2025 & Recent Highlights","length":42,"tagName":"p"},{"type":"text","content":"Advanced Product and Clinical Development","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received ethical approval in Australia to initiate long-term clinical study of the Company’s continuous blood glucose monitor (CBGM) in participant...